ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to determine the Maximum tolerated dose, if any, of the
combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up
to 45 mg/m2 paclitaxel.